癌症患者对药用级合成大麻二酚的客观临床反应报告。
Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol.
作者信息
Kenyon Julian, Liu Wai, Dalgleish Angus
机构信息
The Old Brewery, Winchester Hants, U.K.
St George's University of London, London, U.K.
出版信息
Anticancer Res. 2018 Oct;38(10):5831-5835. doi: 10.21873/anticanres.12924.
BACKGROUND/AIM: Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet. The aim of this study was to assess the effects of pharmaceutical-grade synthetic cannabidiol on a range of cancer patients.
PATIENTS AND METHODS
We analysed the data routinely collected, as part of our treatment program, in 119 cancer patients over a four-year period.
RESULTS
Clinical responses were seen in 92% of the 119 cases with solid tumours including a reduction in circulating tumour cells in many cases and in other cases, a reduction in tumour size, as shown by repeat scans. No side-effects of any kind were observed when using pharmaceutical grade synthetic cannabidiol.
CONCLUSION
Pharmaceutical-grade synthetic cannabidiol is a candidate for treating breast cancer and glioma patients.
背景/目的：大麻素广泛用于癌症患者疼痛、恶心和恶病质的管理。然而，目前尚无任何抗癌活性的客观临床证据。本研究的目的是评估药用级合成大麻二酚对一系列癌症患者的影响。
患者与方法
我们分析了作为治疗方案一部分在四年期间对119例癌症患者常规收集的数据。
结果
119例实体瘤患者中有92%出现临床反应，包括许多病例中循环肿瘤细胞减少，其他病例中肿瘤大小减小，重复扫描显示。使用药用级合成大麻二酚时未观察到任何副作用。
结论
药用级合成大麻二酚是治疗乳腺癌和神经胶质瘤患者的候选药物。
Zotero 插件